Resultados: 17

    The management of myelofibrosis: a British Society for Haematology guideline

    Br. j. haematol; 204 (1), 2024
    This document represents an update of the British Society for Haematology guideline on Myelofibrosis first published in 2012 and updated in 2015 These guidelines aim to pro-vide healthcare professionals with clear guidance on stratified management for primary myelofibrosis (PMF)...

    Guía de práctica clínica para el tratamiento del cáncer de próstata metastásico hormonosensible: guía en versión extensa

    El cáncer de próstata metastásico se presenta en el 20% de pacientes al momento del diagnóstico de cáncer de próstata (1). Los sitios comunes de diseminación metastásica locorregional son los ganglios linfáticos (99%) y huesos como pelvis, cadera y esqueleto axial (84%); mientras que las localiz...

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. Commercial arrangement There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...

    Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)

    NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission....

    Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma

    Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults. Commercial arrangements There is a simple discount patient access scheme for lenvatinib and a commercial access agreement for pembrolizumab. NHS organisations can g...

    Colorectal cancer: Last updated 15 December 2021

    This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease). The recommendations in this guideline were developed befor...

    Problema de Salud AUGE N°83: Cáncer Renal en personas de 15 años y más

    La incidencia del carcinoma de células renales (CCR) ha aumentado en las últimas décadas, siendo a nivel mundial el sexto cáncer más frecuentemente diagnosticado en hombres y el décimo en mujeres (1). Sin embargo, la sobrevida ha mejorado en las últimas tres décadas. Esto se ha dado, en parte, po...

    Colorectal cancer

    This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease)....

    European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

    Eur. j. endocrinol; 178 (1), 2018
    BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with meta...